title: Data from extension trials: denosumab and zoledronic acid.
abstract: Osteoporosis and fractures that occur as a result of this condition pose a huge public health problem to society and result in morbidity and mortality to individuals. Because osteoporosis is often a result of aging, many people are not aware that therapies exist to reduce the risk of fracture. Until recently, the most common therapies used to treat osteoporosis, the oral bisphosphonates, had an inconvenient and cumbersome mode of administration. Within the last 4 years, two new parenteral antiresorptive drugs to treat osteoporosis were approved by the US Food and Drug Administration. As treatment of osteoporosis may extend for many years, the collection of long-term efficacy and safety data is warranted. This paper discusses data from the extension trials of denosumab and zoledronic acid.
authors.affiliation: David Geffen School of Medicine, Division of Rheumatology, UCLA, 18102 Irvine Blvd Suite 104, Tustin, CA 92780, USA. rkdmail@sbcglobal.net
authors.forename: Robin K
authors.initials: RK
authors.lastname: Dore
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D000075202:Contraindications; D003404:Creatinine / Q000097:blood; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D010024:Osteoporosis / Q000188:drug therapy* / Q000453:epidemiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D058866:Osteoporotic Fractures / Q000517:prevention & control; D053245:RANK Ligand / Q000037:antagonists & inhibitors*; D051437:Renal Insufficiency / Q000453:epidemiology; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D053245:RANK Ligand; D000069448:Denosumab; D000077211:Zoledronic Acid; D003404:Creatinine
references.citation: N Engl J Med. 2007 May 3;356(18):1809-22
references.pmid: 17476007
references.citation: Osteoporos Int. 2007 Aug;18(8):1023-31
references.pmid: 17308956
references.citation: N Engl J Med. 2009 Aug 20;361(8):756-65
references.pmid: 19671655
references.citation: J Clin Endocrinol Metab. 2011 Feb;96(2):394-402
references.pmid: 21159841
references.citation: J Bone Miner Res. 2007 Dec;22(12):1832-41
references.pmid: 17708711
references.citation: Bone. 2008 Aug;43(2):222-9
references.pmid: 18539106